Abstract
Combining the PD-L1 inhibitor atezolizumab with standard chemotherapy improves overall survival among patients with metastatic triple-negative breast cancer relative to chemotherapy alone. These findings could lead to a new treatment option for patients with this disease.
- ©2018 American Association for Cancer Research.
Log in using your username and password
Purchase Short Term Access
Pay Per Article - You may access this article (from the computer you are currently using) for 1 day for US$35.00
Regain Access - You can regain access to a recent Pay per Article purchase if your access period has not yet expired.
January 2019
Volume 9, Issue 1
Volume 9, Issue 1
PD-L1 Inhibitor Improves Survival in TNBC
Jump to section
Advertisement